The company posted a net loss of $8.75m, compared to a net loss of $7.31m for the same period in 2009.
Trius’ loss from operations was $9m, as compare to the loss from operations of $6.8m for the same period prior year.
For the full year ended 31 December 2010, the company posted total revenues of $8.03m, compared to $5.02m for the same period in 2009.
Trius has reported net loss of $23.86m, compared to $22.68m for the same period in 2009.
The company’s loss from operations was $20.69m for the full year ended 31 December 2010, as compared to $22.17m for the same period last year.
Trius president and CEO Jeffrey Stein said they have made substantial progress on the development program for their investigational drug, torezolid phosphate.
"In addition to meeting our enrollment projections for our Phase 3 trial in ABSSSI, the positive results of our recently announced Phase 1 torezolid lung study support the use of the same once daily 200mg dose in pneumonia indications in the future," Stein said.
"We continue to evaluate potential strategic alliances for an ex-US territory that reflect the strong value that we have created with torezolid."